Ketoacidosis signal from new diabetes drug class

THE US Food and Drug Administration is warning a new class of type 2 diabetes drugs could lead to diabetic ketoacidosis (DKA).

Sodium-glucose cotransporter-2 (SGLT2) inhibitors dapagliflozin (Forxiga, AstraZeneca), canagliflozin (Invokana, Janssen-Cilag) and empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) reduce reabsorption of glucose in the kidneys leading to urinary glucose excretion, according to MIMS.

The drugs, which were PBS-listed in 2013 (dapagliflozin and canagliflozin) and 2015 (empagliflozin), are available on authority for combination therapy with either metformin or a